Use of Norethisterone oenanthate and predisposition to thrombosis

Nasir Ali Afsar, Qamaruddin Barakzai, Salman Naseem Adil

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Objective: To observe the effects of progestin-only hormonal contraceptives in our population. Design: Cohort study. Place and Duration of Study: Department of Pharmacology, Ziauddin Medical University, Karachi and Department of Pathology, Faculty of Health Sciences, The Aga Khan University, Karachi from October 2002 to September 2003. Patients and Methods: The study comprised of 50 women of reproductive age group, divided into two equal and matched groups of 25 each, namely, a group of users of progestin-only injectable hormonal contraceptive Norethisterone oenanthate [NET EN] 200 μg used as a 2-monthly injection and a control group not using any hormonal contraception. Complete blood counts, prothrombin time (PT) and international normalized ratio (INR) as well as activated partial thromboplastin time (APTT) were monitored. Results: APTT and prothrombin time were not significantly different in both the groups. Menstrual irregularities were found out by more frequent in users of injectable hormonal contraceptives than in non-users (p=0.001). Hemoglobin (p=0.029) and hematocrit were slightly better preserved in the same group. Conclusion: Use of Norethisterone oenanthate does not predispose to thrombogenesis in current dose for contraception.

Original languageEnglish
Pages (from-to)556-559
Number of pages4
JournalJournal of the College of Physicians and Surgeons--Pakistan : JCPSP
Issue number9
Publication statusPublished - Sept 2004


  • APTT
  • Coagulation
  • Contraceptive
  • Norethisterone
  • PT
  • Progestin
  • Thrombophilia
  • Thrombosis


Dive into the research topics of 'Use of Norethisterone oenanthate and predisposition to thrombosis'. Together they form a unique fingerprint.

Cite this